| Pemigatinib studied in …STUDIED_INderived44 of 44show fewer |
|---|
| → studied in | NCT06302621Phase 1 · recruiting Pemigatinib + Afatinib in Advanced Refractory Solid Tumors · 44 trials list this drug (13 active) | — | — | Solid Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07780838Phase 2 · recruiting Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma · 44 trials list this drug (13 active) | — | — | Biliary Tract Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06728410Phase 2 · recruiting A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement · 44 trials list this drug (13 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06389799Phase 2 · recruiting A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) · 44 trials list this drug (13 active) | — | — | Dedifferentiated Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656536Phase 3 · terminated A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma · 44 trials list this drug (13 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659616Phase 1 · recruiting Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia · 44 trials list this drug (13 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06300528Phase 2 · active not recruiting Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas · 44 trials list this drug (13 active) | — | — | Mantle Cell Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04463771Phase 2 · completed Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. · 44 trials list this drug (13 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07434843Phase 2 · recruiting PH 2 Pemigatinib in SDH-deficient GIST · 44 trials list this drug (13 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06906562Phase 2 · recruiting A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations · 44 trials list this drug (13 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267106Phase 2 · terminated Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations · 44 trials list this drug (13 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 44 trials list this drug (13 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03011372Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) · 44 trials list this drug (13 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03822117Phase 2 · terminated Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) · 44 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04003610Phase 2 · terminated Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) · 44 trials list this drug (13 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914794Phase 2 · completed A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors · 44 trials list this drug (13 active) | — | — | Malignant Bladder Neoplasm,Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02872714Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) · 44 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02924376Phase 2 · completed Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) · 44 trials list this drug (13 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253807Phase 2 · completed Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration · 44 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06653777Phase 2 · recruiting Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells · 44 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294277Phase 2 · terminated Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery · 44 trials list this drug (13 active) | — | — | Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05565794Phase 2 · terminated Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements · 44 trials list this drug (13 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04949191Phase 2 · terminated The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. · 44 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06551896Phase 2 · not yet recruiting Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor · 44 trials list this drug (13 active) | — | — | Breast Neoplasm,Carcinoma,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 44 trials list this drug (13 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04256980Phase 2 · completed Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement · 44 trials list this drug (13 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088188Phase 1 · terminated Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma · 44 trials list this drug (13 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05004974Phase 2 · unknown Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer · 44 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04096417Phase 2 · unknown Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations · 44 trials list this drug (13 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 44 trials list this drug (13 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 44 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06022289Phase 2 · unknown Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors · 44 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05997459Phase 2 · unknown A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant · 44 trials list this drug (13 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05216120Phase 2 · withdrawn Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas · 44 trials list this drug (13 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05913661Phase 2 · unknown Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma · 44 trials list this drug (13 active) | — | — | Digestive System Neoplasm,Carcinoma,Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393248Phase 1/Phase 2 · terminated Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) · 44 trials list this drug (13 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05651672Phase 2 · recruiting Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations · 44 trials list this drug (13 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04003623Phase 2 · terminated Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) · 44 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03906357no longer available Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer · 44 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05287386Phase 2 · unknown A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy · 44 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05210946NA · unknown A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients · 44 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202236Phase 2 · unknown A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy · 44 trials list this drug (13 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04258527Phase 1 · completed Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations · 44 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03235570Phase 1 · completed A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) · 44 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |